moxifloxacin has been researched along with physostigmine in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (physostigmine) | Trials (physostigmine) | Recent Studies (post-2010) (physostigmine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 6,230 | 252 | 331 |
| Protein | Taxonomy | moxifloxacin (IC50) | physostigmine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.1666 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.3023 | |
| Cholinesterase | Homo sapiens (human) | 0.3055 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.2 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.0269 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.0853 | |
| Acetylcholinesterase | Bos taurus (cattle) | 0.7197 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 1.1821 | |
| Acetylcholinesterase | Gallus gallus (chicken) | 0.02 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.0416 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Cholinesterase | Equus caballus (horse) | 0.4081 | |
| Cholinesterase | Mus musculus (house mouse) | 0.28 | |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 0.0189 | |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 0.018 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 1.263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and physostigmine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for moxifloxacin and physostigmine
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |